Sarepta (SRPT) May Seek Partner in Europe as Eteplirsen Tests Continue

January 11, 2013 9:21 AM EST
Sarepta Therapeutics (Nasdaq: SRPT) is ticking higher amid chatter that it might seek to form an overseas partnership for its Duchenne muscular dystrophy (DMD) treatment.

Sarepta is in talks with over one dozen potential partners for international slaes of eteplirsen, CEO Christopher Garabedian commented at the J.P. Morgan Healthcare Conference this week. Centerview Partners LLC, JSP Partners, or another firm could be tapped to advise on the matter.

Success with eteplirsen testing might make Sarepta a takeover target, but Garabedian has other ideas. He said that he is hiring talent from larger rivals that want to build a break-out biotech company.

Ahead of the conference this week, Sarepta shares have climbed 480 percent since the close on December 30, 2011. Ahead of the bell today, shares are indicated another 1.8 percent higher.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Rumors, Trader Talk

Related Entities


Add Your Comment